Project CBD

MARCH 21, 2023

Auditory & Other Symptoms The survey, whose findings were published in February 2023 in the Journal of Otolaryngology – Head & Neck Surgery 1 evaluated cannabis perceptions and consumption among 45 adult tinnitus patients randomly selected and recruited from an outpatient ear, nose, and throat clinic in Ontario, Canada.

Cannabinoids 144

Cannabinoids Clinical Trials Sleep Blood Pressure 144

Dykema (Cannabis Law Blog)

APRIL 20, 2023

iii] The Act was originally intended for patients with intractable epilepsy and was expanded in 2019 and 2021 to include other physical and mental illnesses (cancer, multiple sclerosis, post-traumatic stress disorder). [iv] 2 – 3 (2023). Specifically, H.B. Code § 169.001 et seq. [vi] vi] [link] [vii] Tex. 1805, 88th Leg.,

Law 74

Law Chronic Pain Conditions Medicine 74

MMJ Recs

DECEMBER 13, 2023

However, the tide began to turn in 2015 when the state legislature passed the Compassionate Use Act, allowing for the limited use of low-THC cannabis for patients with intractable epilepsy. Qualifying conditions include epilepsy, terminal cancer, multiple sclerosis, autism, and incurable neurodegenerative diseases.

Dispensary 52

Dispensary Patients Marijuana Epilepsy 52

Veriheal

SEPTEMBER 15, 2023

In April 2019, House Bill 324 was approved, enabling in-state cultivation and the sale of low-THC oil. Finally, on April 28, 2023, the first licensed sales commenced with the opening of dispensaries in Marietta and Macon.

Programs 62

Programs Legalization Oil Conditions 62

The Cannigma

JULY 5, 2022

In-state cultivation and distribution weren’t legalized until 2019. Despite having 20,000 registered patients in March of 2022, there are no licensed producers or distributors of cannabis products and sales are unlikely to start before mid-2023 at the earliest. But there were a myriad of problems with the rollout that persist today.

Law 96

Law Decriminalization Programs Patients 96

Cannabis Law Report

DECEMBER 9, 2019

In fact, the Brightfield Group claims that the CBD market may reach $24 billion by 2023, good news for businesses such as Next Green Wave, Inc. The supplement has already been adopted by millions of consumers and boasts a growth trajectory that has investors foaming at the mouth to get in on the action. Anxiety and Inflammation Lead the Pack.

Pets 59

Pets CBD Research and Development Epilepsy 59

Veriheal

SEPTEMBER 2, 2022

Individuals in the country with conditions such as Parkinson’s disease, depression, insomnia, ADHD, multiple sclerosis, anxiety, chronic pain, and epilepsy have embraced the option of medical cannabis. estimates that 60-70% of his patients are seeking out medical cannabis for the treatment of chronic pain.

Chronic Pain 57

Chronic Pain Patients Decriminalization Cannabis 57